 | • レポートコード：GIR-107A14668 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、多関節若年性特発性関節炎治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。多関節若年性特発性関節炎治療薬の種類別市場規模（エタネルセプトバイオシミラー、トシリズマブバイオシミラー、サリルマブ、アダリムマブバイオシミラー、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・多関節若年性特発性関節炎治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Biocon Ltd、Coherus BioSciences Inc、Livzon Pharmaceutical Group Inc、Momenta Pharmaceuticals Inc、Mycenax Biotech Inc、Oncobiologics Inc、Oncodesign SA、Panacea Biotec Ltd、Regeneron Pharmaceuticals Inc、Sandoz International GmbH、UCB SA ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：エタネルセプトバイオシミラー、トシリズマブバイオシミラー、サリルマブ、アダリムマブバイオシミラー、その他 ・用途別分析2016年-2026年：病院、クリニック、その他 ・多関節若年性特発性関節炎治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・多関節若年性特発性関節炎治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・多関節若年性特発性関節炎治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・多関節若年性特発性関節炎治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・多関節若年性特発性関節炎治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Polyarticular Juvenile Idiopathic Arthritis Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Polyarticular Juvenile Idiopathic Arthritis Drug size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Polyarticular Juvenile Idiopathic Arthritis Drug market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Polyarticular Juvenile Idiopathic Arthritis Drug market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Etanercept Biosimilar
Tocilizumab Biosimilar
Sarilumab
Adalimumab Biosimilar
Others
Market segment by Application can be divided into
Hospital
Clinic
Others
The key market players for global Polyarticular Juvenile Idiopathic Arthritis Drug market are listed below:
Biocon Ltd
Coherus BioSciences Inc
Livzon Pharmaceutical Group Inc
Momenta Pharmaceuticals Inc
Mycenax Biotech Inc
Oncobiologics Inc
Oncodesign SA
Panacea Biotec Ltd
Regeneron Pharmaceuticals Inc
Sandoz International GmbH
UCB SA
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Polyarticular Juvenile Idiopathic Arthritis Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Polyarticular Juvenile Idiopathic Arthritis Drug, with price, sales, revenue and global market share of Polyarticular Juvenile Idiopathic Arthritis Drug from 2019 to 2021.
Chapter 3, the Polyarticular Juvenile Idiopathic Arthritis Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Polyarticular Juvenile Idiopathic Arthritis Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Polyarticular Juvenile Idiopathic Arthritis Drug market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Polyarticular Juvenile Idiopathic Arthritis Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Polyarticular Juvenile Idiopathic Arthritis Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Etanercept Biosimilar
1.2.3 Tocilizumab Biosimilar
1.2.4 Sarilumab
1.2.5 Adalimumab Biosimilar
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Size & Forecast
1.4.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales in Value (2016-2026))
1.4.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales in Volume (2016-2026)
1.4.3 Global Polyarticular Juvenile Idiopathic Arthritis Drug Price by Type (2016-2026) & (USD/Pcs)
1.5 Global Polyarticular Juvenile Idiopathic Arthritis Drug Production Capacity Analysis
1.5.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Total Production Capacity (2016-2026)
1.5.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Polyarticular Juvenile Idiopathic Arthritis Drug Market Drivers
1.6.2 Polyarticular Juvenile Idiopathic Arthritis Drug Market Restraints
1.6.3 Polyarticular Juvenile Idiopathic Arthritis Drug Trends Analysis
2 Manufacturers Profiles
2.1 Biocon Ltd
2.1.1 Biocon Ltd Details
2.1.2 Biocon Ltd Major Business
2.1.3 Biocon Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
2.1.4 Biocon Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Coherus BioSciences Inc
2.2.1 Coherus BioSciences Inc Details
2.2.2 Coherus BioSciences Inc Major Business
2.2.3 Coherus BioSciences Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
2.2.4 Coherus BioSciences Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Livzon Pharmaceutical Group Inc
2.3.1 Livzon Pharmaceutical Group Inc Details
2.3.2 Livzon Pharmaceutical Group Inc Major Business
2.3.3 Livzon Pharmaceutical Group Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
2.3.4 Livzon Pharmaceutical Group Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Momenta Pharmaceuticals Inc
2.4.1 Momenta Pharmaceuticals Inc Details
2.4.2 Momenta Pharmaceuticals Inc Major Business
2.4.3 Momenta Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
2.4.4 Momenta Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Mycenax Biotech Inc
2.5.1 Mycenax Biotech Inc Details
2.5.2 Mycenax Biotech Inc Major Business
2.5.3 Mycenax Biotech Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
2.5.4 Mycenax Biotech Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Oncobiologics Inc
2.6.1 Oncobiologics Inc Details
2.6.2 Oncobiologics Inc Major Business
2.6.3 Oncobiologics Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
2.6.4 Oncobiologics Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Oncodesign SA
2.7.1 Oncodesign SA Details
2.7.2 Oncodesign SA Major Business
2.7.3 Oncodesign SA Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
2.7.4 Oncodesign SA Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Panacea Biotec Ltd
2.8.1 Panacea Biotec Ltd Details
2.8.2 Panacea Biotec Ltd Major Business
2.8.3 Panacea Biotec Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
2.8.4 Panacea Biotec Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Regeneron Pharmaceuticals Inc
2.9.1 Regeneron Pharmaceuticals Inc Details
2.9.2 Regeneron Pharmaceuticals Inc Major Business
2.9.3 Regeneron Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
2.9.4 Regeneron Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 Sandoz International GmbH
2.10.1 Sandoz International GmbH Details
2.10.2 Sandoz International GmbH Major Business
2.10.3 Sandoz International GmbH Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
2.10.4 Sandoz International GmbH Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.11 UCB SA
2.11.1 UCB SA Details
2.11.2 UCB SA Major Business
2.11.3 UCB SA Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
2.11.4 UCB SA Polyarticular Juvenile Idiopathic Arthritis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Manufacturer
3.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Polyarticular Juvenile Idiopathic Arthritis Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Polyarticular Juvenile Idiopathic Arthritis Drug Manufacturer Market Share
3.4.2 Top 6 Polyarticular Juvenile Idiopathic Arthritis Drug Manufacturer Market Share
3.5 Global Polyarticular Juvenile Idiopathic Arthritis Drug Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Polyarticular Juvenile Idiopathic Arthritis Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Size by Region
4.1.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales in Volume by Region (2016-2026)
4.1.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Region (2016-2026)
4.2 North America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue (2016-2026)
4.3 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Revenue (2016-2026)
4.4 Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Revenue (2016-2026)
4.5 South America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue (2016-2026)
4.6 Middle East and Africa Polyarticular Juvenile Idiopathic Arthritis Drug Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales in Volume by Type (2016-2026)
5.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Type (2016-2026)
5.3 Global Polyarticular Juvenile Idiopathic Arthritis Drug Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales in Volume by Application (2016-2026)
6.2 Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Application (2016-2026)
6.3 Global Polyarticular Juvenile Idiopathic Arthritis Drug Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2016-2026)
7.2 North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2016-2026)
7.3 North America Polyarticular Juvenile Idiopathic Arthritis Drug Market Size by Country
7.3.1 North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales in Volume by Country (2016-2026)
7.3.2 North America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2016-2026)
8.2 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2016-2026)
8.3 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Market Size by Country
8.3.1 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales in Volume by Country (2016-2026)
8.3.2 Europe Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2016-2026)
9.2 Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2016-2026)
9.3 Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Market Size by Region
9.3.1 Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2016-2026)
10.2 South America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2016-2026)
10.3 South America Polyarticular Juvenile Idiopathic Arthritis Drug Market Size by Country
10.3.1 South America Polyarticular Juvenile Idiopathic Arthritis Drug Sales in Volume by Country (2016-2026)
10.3.2 South America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2016-2026)
11.2 Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2016-2026)
11.3 Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Market Size by Country
11.3.1 Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Polyarticular Juvenile Idiopathic Arthritis Drug Typical Distributors
12.3 Polyarticular Juvenile Idiopathic Arthritis Drug Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Type, (USD Million), 2021-2026
Table 2. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Application, (USD Million), 2021-2026
Table 3. Biocon Ltd Basic Information, Manufacturing Base and Competitors
Table 4. Biocon Ltd Major Business
Table 5. Biocon Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
Table 6. Biocon Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Coherus BioSciences Inc Basic Information, Manufacturing Base and Competitors
Table 8. Coherus BioSciences Inc Major Business
Table 9. Coherus BioSciences Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
Table 10. Coherus BioSciences Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Livzon Pharmaceutical Group Inc Basic Information, Manufacturing Base and Competitors
Table 12. Livzon Pharmaceutical Group Inc Major Business
Table 13. Livzon Pharmaceutical Group Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
Table 14. Livzon Pharmaceutical Group Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Momenta Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 16. Momenta Pharmaceuticals Inc Major Business
Table 17. Momenta Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
Table 18. Momenta Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Mycenax Biotech Inc Basic Information, Manufacturing Base and Competitors
Table 20. Mycenax Biotech Inc Major Business
Table 21. Mycenax Biotech Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
Table 22. Mycenax Biotech Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Oncobiologics Inc Basic Information, Manufacturing Base and Competitors
Table 24. Oncobiologics Inc Major Business
Table 25. Oncobiologics Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
Table 26. Oncobiologics Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Oncodesign SA Basic Information, Manufacturing Base and Competitors
Table 28. Oncodesign SA Major Business
Table 29. Oncodesign SA Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
Table 30. Oncodesign SA Polyarticular Juvenile Idiopathic Arthritis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Panacea Biotec Ltd Basic Information, Manufacturing Base and Competitors
Table 32. Panacea Biotec Ltd Major Business
Table 33. Panacea Biotec Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
Table 34. Panacea Biotec Ltd Polyarticular Juvenile Idiopathic Arthritis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Regeneron Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 36. Regeneron Pharmaceuticals Inc Major Business
Table 37. Regeneron Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
Table 38. Regeneron Pharmaceuticals Inc Polyarticular Juvenile Idiopathic Arthritis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Sandoz International GmbH Basic Information, Manufacturing Base and Competitors
Table 40. Sandoz International GmbH Major Business
Table 41. Sandoz International GmbH Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
Table 42. Sandoz International GmbH Polyarticular Juvenile Idiopathic Arthritis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. UCB SA Basic Information, Manufacturing Base and Competitors
Table 44. UCB SA Major Business
Table 45. UCB SA Polyarticular Juvenile Idiopathic Arthritis Drug Product and Services
Table 46. UCB SA Polyarticular Juvenile Idiopathic Arthritis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 47. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Manufacturer (2019-2021e) & (K Pcs)
Table 48. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 49. Market Position of Manufacturers in Polyarticular Juvenile Idiopathic Arthritis Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 50. Global Polyarticular Juvenile Idiopathic Arthritis Drug Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 51. Head Office and Polyarticular Juvenile Idiopathic Arthritis Drug Production Site of Key Manufacturer
Table 52. Polyarticular Juvenile Idiopathic Arthritis Drug New Entrant and Capacity Expansion Plans
Table 53. Polyarticular Juvenile Idiopathic Arthritis Drug Mergers & Acquisitions in the Past Five Years
Table 54. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Region (2016-2021e) & (K Pcs)
Table 55. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Region (2021-2026) & (K Pcs)
Table 56. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Region (2016-2021e) & (USD Million)
Table 57. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Region (2021-2026) & (USD Million)
Table 58. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 59. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2021-2026) & (K Pcs)
Table 60. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Type (2016-2021e) & (USD Million)
Table 61. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Type (2021-2026) & (USD Million)
Table 62. Global Polyarticular Juvenile Idiopathic Arthritis Drug Price by Type (2016-2021e) & (USD/Pcs)
Table 63. Global Polyarticular Juvenile Idiopathic Arthritis Drug Price by Type (2021-2026) & (USD/Pcs)
Table 64. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 65. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2021-2026) & (K Pcs)
Table 66. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Application (2016-2021e) & (USD Million)
Table 67. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Application (2021-2026) & (USD Million)
Table 68. Global Polyarticular Juvenile Idiopathic Arthritis Drug Price by Application (2016-2021e) & (USD/Pcs)
Table 69. Global Polyarticular Juvenile Idiopathic Arthritis Drug Price by Application (2021-2026) & (USD/Pcs)
Table 70. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Country (2016-2021e) & (K Pcs)
Table 71. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Country (2021-2026) & (K Pcs)
Table 72. North America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country (2016-2021e) & (USD Million)
Table 73. North America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country (2021-2026) & (USD Million)
Table 74. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 75. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2021-2026) & (K Pcs)
Table 76. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 77. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2021-2026) & (K Pcs)
Table 78. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Country (2016-2021e) & (K Pcs)
Table 79. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Country (2021-2026) & (K Pcs)
Table 80. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country (2016-2021e) & (USD Million)
Table 81. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country (2021-2026) & (USD Million)
Table 82. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 83. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2021-2026) & (K Pcs)
Table 84. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 85. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2021-2026) & (K Pcs)
Table 86. Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Region (2016-2021e) & (K Pcs)
Table 87. Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Region (2021-2026) & (K Pcs)
Table 88. Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Region (2016-2021e) & (USD Million)
Table 89. Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Region (2021-2026) & (USD Million)
Table 90. Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 91. Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2021-2026) & (K Pcs)
Table 92. Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 93. Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2021-2026) & (K Pcs)
Table 94. South America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Country (2016-2021e) & (K Pcs)
Table 95. South America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Country (2021-2026) & (K Pcs)
Table 96. South America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country (2016-2021e) & (USD Million)
Table 97. South America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country (2021-2026) & (USD Million)
Table 98. South America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 99. South America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2021-2026) & (K Pcs)
Table 100. South America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 101. South America Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2021-2026) & (K Pcs)
Table 102. Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Country (2016-2021e) & (K Pcs)
Table 103. Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Country (2021-2026) & (K Pcs)
Table 104. Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country (2016-2021e) & (USD Million)
Table 105. Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Revenue by Country (2021-2026) & (USD Million)
Table 106. Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 107. Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Type (2021-2026) & (K Pcs)
Table 108. Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 109. Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales by Application (2021-2026) & (K Pcs)
Table 110. Direct Channel Pros & Cons
Table 111. Indirect Channel Pros & Cons
Table 112. Polyarticular Juvenile Idiopathic Arthritis Drug Typical Distributors
Table 113. Polyarticular Juvenile Idiopathic Arthritis Drug Typical Customers
List of Figures
Figure 1. Polyarticular Juvenile Idiopathic Arthritis Drug Picture
Figure 2. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Type in 2020
Figure 3. Etanercept Biosimilar
Figure 4. Tocilizumab Biosimilar
Figure 5. Sarilumab
Figure 6. Adalimumab Biosimilar
Figure 7. Others
Figure 8. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Application in 2020
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Size, (USD Million) & (K Pcs): 2020 VS 2021 VS 2026
Figure 13. Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Size and Forecast (2016-2026) & (USD Million)
Figure 14. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales (2016-2026) & (K Pcs)
Figure 15. Global Polyarticular Juvenile Idiopathic Arthritis Drug Price by Type (2016-2026) & (USD/Pcs)
Figure 16. Global Polyarticular Juvenile Idiopathic Arthritis Drug Production Capacity (2016-2026) & (K Pcs)
Figure 17. Global Polyarticular Juvenile Idiopathic Arthritis Drug Production Capacity by Geographic Region: 2020 VS 2021
Figure 18. Polyarticular Juvenile Idiopathic Arthritis Drug Market Drivers
Figure 19. Polyarticular Juvenile Idiopathic Arthritis Drug Market Restraints
Figure 20. Polyarticular Juvenile Idiopathic Arthritis Drug Market Trends
Figure 21. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Manufacturer in 2020
Figure 22. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Manufacturer in 2020
Figure 23. Polyarticular Juvenile Idiopathic Arthritis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 24. Top 3 Polyarticular Juvenile Idiopathic Arthritis Drug Manufacturer (Revenue) Market Share in 2020
Figure 25. Top 6 Polyarticular Juvenile Idiopathic Arthritis Drug Manufacturer (Revenue) Market Share in 2020
Figure 26. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Region (2016-2026)
Figure 27. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Region (2016-2026)
Figure 28. North America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue (2016-2026) & (USD Million)
Figure 29. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Revenue (2016-2026) & (USD Million)
Figure 30. Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Revenue (2016-2026) & (USD Million)
Figure 31. South America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue (2016-2026) & (USD Million)
Figure 32. Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Revenue (2016-2026) & (USD Million)
Figure 33. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Type (2016-2026)
Figure 34. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Type (2016-2026)
Figure 35. Global Polyarticular Juvenile Idiopathic Arthritis Drug Price by Type (2016-2026) & (USD/Pcs)
Figure 36. Global Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Application (2016-2026)
Figure 37. Global Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Application (2016-2026)
Figure 38. Global Polyarticular Juvenile Idiopathic Arthritis Drug Price by Application (2016-2026) & (USD/Pcs)
Figure 39. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Type (2016-2026)
Figure 40. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Application (2016-2026)
Figure 41. North America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Country (2016-2026)
Figure 42. North America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Country (2016-2026)
Figure 43. United States Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Canada Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Mexico Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Type (2016-2026)
Figure 47. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Application (2016-2026)
Figure 48. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Country (2016-2026)
Figure 49. Europe Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Country (2016-2026)
Figure 50. Germany Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Region (2016-2026)
Figure 56. Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Region (2016-2026)
Figure 58. Asia-Pacific Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Region (2016-2026)
Figure 59. China Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Japan Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Korea Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. India Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Southeast Asia Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Australia Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Type (2016-2026)
Figure 66. South America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Application (2016-2026)
Figure 67. South America Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Country (2016-2026)
Figure 68. South America Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Country (2016-2026)
Figure 69. Brazil Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Type (2016-2026)
Figure 72. Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Application (2016-2026)
Figure 73. Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Sales Market Share by Country (2016-2026)
Figure 74. Middle East & Africa Polyarticular Juvenile Idiopathic Arthritis Drug Revenue Market Share by Country (2016-2026)
Figure 75. Turkey Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Egypt Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Saudi Arabia Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. South Africa Polyarticular Juvenile Idiopathic Arthritis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source
世界の特発性血小板減少性紫斑病（ITP）治療市場 2021：企業別、地域別、種類・用途別 The Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value ch…- 乾癬性関節炎治療薬市場：世界及び中国市場分析・予測（～2024年） Psoriatic Arthritis Drug Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Psoriatic Arthritis Drug industry with a focus on the Chinese market. The report provides key statistics on the market status of the Psoriatic Arthritis …
- 世界の乾癬性関節炎治療薬市場予測（～2024年） Psoriatic arthritis is a chronic autoimmune inflammatory disorder that causes inflammation, swelling, and stiffness at any joint of the body. Psoriatic arthritis is a progressive form of psoriasis, characterized by the itchy, scaly red patches on the skin. Scope of the Report: Asia Pacific is antici…
- 世界の若年性黄斑変性症治療市場 2021：企業別、地域別、種類・用途別 The Juvenile Macular Degeneration Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizatio…
- 世界のインターフェロンアルファ-2bバイオシミラー市場 2021：企業別、地域別、種類・用途別 The Interferon Alpha-2b Biosimilar market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade …